首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccl7 |
| Uniprot No | P80098 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-99aa |
| 氨基酸序列 | QPVGINTSTT CCYRFINKKI PKQRLESYRR TTSSHCPREA VIFKTKLDKE ICADPTQKWV QDFMKHLDKK TQTPKL |
| 预测分子量 | 9.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Production and functional characterization of recombinant CCL7 as a potential therapeutic agent in inflammation"**
- 作者：Lee S et al.
- 摘要：研究报道了在大肠杆菌中高效表达并纯化重组CCL7蛋白，验证其体外趋化单核细胞和T细胞的能力，并表明其在小鼠炎症模型中减轻组织损伤的潜在治疗作用。
2. **"CCL7/MCP-3: A novel macrophage chemoattractant in tumor microenvironment via recombinant protein analysis"**
- 作者：Zhang Y et al.
- 摘要：通过重组CCL7蛋白实验，揭示其在肿瘤微环境中通过激活CCR1/CCR3受体招募巨噬细胞，促进血管生成和肿瘤进展的机制。
3. **"Structural and functional comparison of human and murine recombinant CCL7 in viral infection models"**
- 作者：Müller K et al.
- 摘要：对比人与小鼠重组CCL7蛋白的结构差异，发现两者在结合CCR2受体及调控疱疹病毒感染中的趋化活性存在物种特异性差异。
4. **"Recombinant CCL7 modulates dendritic cell migration and adaptive immunity in a murine asthma study"**
- 作者：Park J et al.
- 摘要：利用重组CCL7蛋白处理树突状细胞，证实其通过增强CCR2信号通路促进淋巴结迁移，加剧过敏性哮喘模型的Th2免疫应答。
注：以上内容为模拟文献示例，实际引用需以真实发表论文为准。
Ccl7 (C-C motif chemokine ligand 7), also known as monocyte chemoattractant protein-3 (MCP-3), is a small secreted protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting leukocytes, including monocytes, dendritic cells, and T lymphocytes, to sites of inflammation or injury. Ccl7 binds to multiple G protein-coupled receptors, primarily CCR1. CCR2. and CCR3. initiating signaling cascades that mediate cell migration and activation. Its expression is induced in various cell types, such as fibroblasts, endothelial cells, and macrophages, in response to pro-inflammatory cytokines (e.g., TNF-α, IL-1β) or pathogenic stimuli.
Recombinant Ccl7 protein is produced using engineered expression systems (e.g., E. coli, mammalian cells) to ensure high purity and bioactivity while eliminating animal-derived contaminants. This allows precise control over protein concentration and functionality for experimental or therapeutic applications. Researchers utilize recombinant Ccl7 to study its involvement in inflammatory diseases (e.g., arthritis, atherosclerosis), cancer progression (modulating tumor microenvironment), and infectious responses. In vitro, it is applied in chemotaxis assays, immune cell differentiation studies, and receptor interaction analyses. In vivo, it helps model diseases driven by leukocyte infiltration. Notably, Ccl7’s dual role in promoting inflammation and tissue repair highlights its therapeutic potential as a target or tool in immunomodulation. However, its pleiotropic effects necessitate careful evaluation in context-specific studies.
×
